BGBain Gretchen

Bain Gretchen

*This is an algorithmically generated author record based on publicly available information.

Bain Gretchen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Guangyan Wei

    Divison of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

    1 shared publication
  • Heansika Matta

    Divison of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

    1 shared publication
  • Jing Wang

    Division of Gastroenterology and Hepatology, Renmin Hospital, Wuhan University, Wuhan, Hubei, China

    1 shared publication
  • Ping An

    Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China

    1 shared publication
  • Pinzhu Huang

    Divison of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

    1 shared publication
  • Wenda Li

    Divison of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

    1 shared publication

Latest Publications

  • Open Access

    A novel cell-permeable LOXL2 inhibitor PAT-1251 potently suppresses biliary liver fibrosis via collagen crosslinking-dependent and -independent mechanisms

    by Ping An, Guangyan Wei, Pinzhu Huang, Heansika Matta, Wenda Li, Yi Lin, Jing Wang, Bain Gretchen, Yury V. Popov

    Background: LOXL2 promotes fibrosis through extracellular collagen crosslinking and intracellular signaling mechanisms. Here, we studied the mode of action of a novel potent, cell-permeable LOXL2 inhibitor PAT-1251 on hepatic fibrosis. Methods: PAT-1251 was tested in direct comparison to the anti-LOXL2 mAb AB0023 in the Mdr2−/− biliary fibrosis model of pre-established fibrosis. The direct cellular effects of PAT-1251 (0.1–10 µM) or AB0023 mAb (30 µg/mL) were studied in primary HSC and EpCAM+ progenitor cell (HPC) cultures in vitro. Results: Both PAT-1251 and AB0023 were effective at inhibiting collagen crosslinking and reducing portal hypertension and serum transaminase (ALT) levels. Histologically, the placebo-treated group developed severe periportal and perisinusoidal fibrosis with bridging, which was markedly attenuated in PAT-1251–treated mice, with up to 77.7% reduction in hepatic collagen deposition with the high-dose PAT-1251. Treatment with the low dose of PAT-1251 or AB0023 resulted in a moderate improvement in hepatic fibrosis and a modest reduction in collagen deposition. PAT-1251, but not AB0023, significantly reduced ductular proliferation and favored hepatocyte-driven liver regeneration in vivo. In vitro, PAT-1251 promoted colony formation and hepatocyte differentiation in EpCAM+ HPC and dose-dependently inhibited α-SMA expression, cell proliferation, and fibrogenic gene expression in HSC, while the anti-LOXL2 antibody AB0023 had no substantial effect. Conclusions: While having comparable extracellular effects on collagen crosslinking in vivo, the cell-permeable LOXL2 inhibitor PAT-1251 exerted potent antifibrotic activity in hepatic progenitors and HSC cultures compared with the anti-LOXL2 antibody. PAT-1251 substantially outperformed the anti-LOXL2 antibody in the BALB/c. Mdr2−/− model of biliary fibrosis, suggesting that intracellular LOXL2 targeting is therapeutically important in addition to its well-characterized extracellular collagen crosslinking activity.